Katrina A B Goddard

List of Publications by Year
in descending order

46 papers	1,565 citations	304743 22 h-index	315739 38 g-index
47 all docs	47 docs citations	47 times ranked	2806 citing authors

#	Article	IF	Citations
1	ClinGenâ€™s Pediatric Actionability Working Group: Clinical actionability of secondary findings from genome-scale sequencing in children and adolescents. Genetics in Medicine, 2022, 24, 1328-1335.	2.4	4
2	Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system. Hereditary Cancer in Clinical Practice, 2022, 20, 17.	1.5	4
3	Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders. Genetics in Medicine, 2019, 21, 2561-2568.	2.4	4
4	Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Familial Cancer, 2019, 18, 317-325.	1.9	6
5	Recommended care and care adherence following a diagnosis of Lynch syndrome: a mixed-methods study. Hereditary Cancer in Clinical Practice, 2019, 17, 31.	1.5	14
6	The evolving landscape of expanded carrier screening: challenges and opportunities. Genetics in Medicine, 2019, 21, 790-797.	2.4	90
7	Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings. Genetics in Medicine, 2018, 20, 1186-1195.	2.4	11
8	Time Costs for Genetic Counseling in Preconception Carrier Screening with Genome Sequencing. Journal of Genetic Counseling, 2018, 27, 823-833.	1.6	22
9	Patient perspectives on the use of categories of conditions for decision making about genomic carrier screening results. American Journal of Medical Genetics, Part A, 2018, 176, 376-385.	1.2	21
10	Evidenceâ€based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group. Human Mutation, 2018, 39, 1677-1685.	2.5	34
11	Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience. Molecular Genetics & Genomic Medicine, 2018, 6, 898-909.	1.2	15
12	Lessons Learned From A Study Of Genomics-Based Carrier Screening For Reproductive Decision Making. Health Affairs, 2018, 37, 809-816.	5.2	10
13	Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening. PLoS ONE, 2018, 13, e0200139.	2.5	19
14	Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory. American Journal of Human Genetics, 2018, 102, 1078-1089.	6.2	35
15	Genome sequencing and carrier testing: decisions on categorization and whether to disclose results of carrier testing. Genetics in Medicine, 2017, 19, 803-808.	2.4	24
16	Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Familial Cancer, 2017, 16, 377-387.	1.9	11
17	Reasons for Declining Preconception Expanded Carrier Screening Using Genome Sequencing. Journal of Genetic Counseling, 2017, 26, 971-979.	1.6	37
18	Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing. Contemporary Clinical Trials, 2017, 53, 100-105.	1.8	26

#	Article	IF	Citations
19	The NextGen Study: patient motivation for participation in genome sequencing for carrier status. Molecular Genetics & Genomic Medicine, 2017, 5, 508-515.	1.2	20
20	A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genetics in Medicine, 2017, 19, 575-582.	2.4	68
21	Generating a taxonomy for genetic conditions relevant to reproductive planning. American Journal of Medical Genetics, Part A, 2016, 170, 565-573.	1.2	25
22	A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. Genetics in Medicine, 2016, 18, 1258-1268.	2.4	89
23	Patients' ratings of genetic conditions validate a taxonomy to simplify decisions about preconception carrier screening via genome sequencing. American Journal of Medical Genetics, Part A, 2016, 170, 574-582.	1.2	20
24	â€œIs It Worth Knowing?â€•Focus Group Participantsâ€™ Perceived Utility of Genomic Preconception Carrier Screening. Journal of Genetic Counseling, 2016, 25, 135-145.	1.6	44
25	It's complicated: criteria for policy decisions for the clinical integration of genomeâ€scale sequencing for reproductive decision making. Molecular Genetics & Genomic Medicine, 2015, 3, 239-242.	1.2	19
26	Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer, 2015, 15, 156.	2.6	81
27	Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer, 2015, 121, 3281-3289.	4.1	30
28	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	6.2	342
29	Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genetics in Medicine, 2013, 15, 721-728.	2.4	40
30	Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects. Journal of the National Cancer Institute, 2013, 105, 929-936.	6.3	30
31	Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genetics in Medicine, 2013, 15, 933-940.	2.4	45
32	Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy Exposure. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 673-680.	2.5	19
33	Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genetics in Medicine, 2012, 14, 633-642.	2.4	36
34	Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genetics in Medicine, 2012, 14, 656-662.	2.4	24
35	Utilization of HER2 genetic testing in a multi-institutional observational study. American Journal of Managed Care, 2012, 18, 704-12.	1.1	10
36	A Confidenceâ€Limitâ€Based Approach to the Assessment of Hardyâ€“Weinberg Equilibrium. Biometrical Journal, 2010, 52, 253-270.	1.0	15

#	Article	IF	Citations
37	Dengue hemorrhagic fever is associated with polymorphisms in JAK1. European Journal of Human Genetics, 2010, 18, 1221-1227.	2.8	45
38	Association mapping by generalized linear regression with densityâ€based haplotype clustering. Genetic Epidemiology, 2009, 33, 16-26.	1.3	6
39	Adapting the logical basis of tests for Hardyâ€Weinberg Equilibrium to the real needs of association studies in human and medical genetics. Genetic Epidemiology, 2009, 33, 569-580.	1.3	9
40	Public Awareness and Use of Direct-to-Consumer Genetic Tests: Results From 3 State Population-Based Surveys, 2006. American Journal of Public Health, 2009, 99, 442-445.	2.7	37
41	Awareness and use of direct-to-consumer nutrigenomic tests, United States, 2006. Genetics in Medicine, 2007, 9, 510-517.	2.4	56
42	Density-based clustering in haplotype analysis for association mapping. BMC Proceedings, 2007, 1, S27.	1.6	5
43	Issues in association mapping with high-density SNP data and diverse family structures. Genetic Epidemiology, 2007, 31, S22-S33.	1.3	4
44	HLA-DQA Is Associated with Abdominal Aortic Aneurysms in the Belgian Population. Annals of the New York Academy of Sciences, 2006, 1085, 392-395.	3.8	9
45	Beta 2 adrenergic receptor polymorphisms in cystic fibrosis. Pediatric Pulmonology, 2005, 39, 544-550.	2.0	16
46	Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. Neurogenetics, 2004, 5, 121-128.	1.4	27